Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Everyday Health on MSN
New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight
The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much weight loss comes with risks.
Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
GLP-1 RAs probably have little or no effect on risk for thyroid cancer, pancreatic cancer, breast cancer, or kidney cancer.
Phoenix NP announced a continued rise in patient satisfaction across Arizona, noting that positive feedback has increased as more women seek safe, FDA-approved GLP-1 weight loss medications through ...
Dec 12 (Reuters) - The European Medicines Agency's committee on Friday recommended extending the use of Eli Lilly's ...
TecFut is one of the banners of Julio Casares' management, who has usually invited journalists over the past five years to ...
Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...
Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...
The global health organization now officially backs drugs like Wegovy for obesity management. But it might be more symbolic ...
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback